Early-stage partnerships have evolved over the years and are now back in vogue with big pharma partners. While the actual number of early-stage deals completed by big pharma declined over the past four years, the number and value of blockbuster early-stage deals has increased dramatically of late. Deal structures evolved, with many types being vetted and new structures introduced. Currently, deals are focusing on the delivery of clinical proof of concept as the key value-driving component. Hear real deal-makers discuss and analyze the latest trends in partnering and provide insights into successful alliance formation.

Objective1: Summarize the latest trends in partnering activity, including deal structures and valuation.

Objective2: Discuss implications of various partnering strategies including addressing financing needs in a time of lackluster markets.

Objective3: Provide guidance for biotech companies on how to best allocate R&D funding to generate successful outcomes and to create and retain greater value.